Tenax Therapeutics, Inc. Securities Fraud Class Action Lawsuit - TENX

Tenax Therapeutics, Inc.
NASDAQ: TENX

Affected TENX Investor Summary

- **Who:** Tenax Therapeutics, Inc. (NASDAQ: TENX)
- **What:** Securities fraud class action lawsuit filed
- **Class Period:** November 13, 2023 through August 7, 2026
- **Deadline to Seek Lead Plaintiff Status:** December 28, 2026
- **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the efficacy of the company's lead product candidate
- **Investor Action:** Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options

---

The *Tenax Therapeutics, Inc.* securities fraud class action lawsuit was filed on behalf of those who purchased or otherwise acquired *Tenax Therapeutics, Inc.* ("*Tenax*") (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026, inclusive (the "Class Period"). Captioned *Katz v. Tenax Therapeutics, Inc.,* No. 26-cv-01264 (M.D.N.C.), the *Tenax* class action lawsuit alleges that *Tenax* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you lost money as a result of your *Tenax* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at info@ktmc.com. Lead plaintiff motions must be filed with the court no later than December 28, 2026.

COMPLAINT ALLEGATION SUMMARY:
Tenax is a Phase 3, development-stage pharmaceutical company that develops novel cardiopulmonary therapies. Its lead product candidate, levosimendan, was evaluated through its Phase 3 LEVEL study of oral levosimendan, or TNX-103, for use in patients with pulmonary hypertension in heart failure with preserved ejection fraction.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) TNX-103 was less effective than the company had touted; (2) accordingly, TNX-103's overall clinical, regulatory, and commercial prospects were overstated; and (3) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHY DID TENAX'S STOCK DROP?

On August 10, 2026, *Tenax* issued a press release reporting disappointing topline results from its Phase 3 LEVEL clinical trial, revealing that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score." On this news, the price of *Tenax's* stock fell nearly 90%.

THE LEAD PLAINTIFF PROCESS:

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *Tenax* securities during the Class Period to seek appointment as lead plaintiff in the *Tenax* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.